The strongest growth outlook in over two years is approaching! US medical device stocks still need to endure another sluggish earnings season
The third-quarter profit growth of medical device companies is expected to be only 4.8%, but it is projected to accelerate to 13% in the first quarter of next year, marking the strongest performance in over two years. However, policy uncertainties and product recalls have dampened confidence, and the market is awaiting a recovery by 2027.
Smart Finance APP notes that medical device companies are set to experience another sluggish earnings season, and will then enter 2027 with the strongest growth outlook in more than two years—after the sector endured a tough period marked by policy uncertainty, cyberattacks, and product recalls.
According to industry research data, sector-wide third-quarter earnings are expected to grow 4.8% year-on-year, weaker than the previous quarter and lagging behind the projected gains for the US benchmark stock index. By the first quarter of next year, this growth rate is expected to accelerate to 13%, marking the strongest performance for the sector since the end of 2024.
Despite modest expectations for the third quarter, Citi analyst Joanne Winsh and others remain optimistic about “localized growth highlights” emerging next year, while Barclays’ Christopher Pasquale expects revenue growth to stabilize.
The S&P 500 Health Care Equipment & Supplies Index—which includes pacemaker manufacturer Medtronic (MDT.US), hip replacement device maker Stryker (SYK.US), and surgical robotics firm Intuitive Surgical (ISRG.US)—has dropped more than 20% year-to-date. Over the same period, the broader market index has gained 13%.
Medical technology sector profit growth is expected to slow before a rebound
The medical device sector has been relatively immune to impacts from tariffs and energy shocks, but uncertainty surrounding possible changes to the Affordable Care Act and Medicaid programs under the “Inflation Reduction Act” has continued to weigh on market sentiment.
Industry research analyst Matt Henriksen said: “The sector’s status as a ‘safe haven’ has diminished.”
Evercore ISI analyst Vijay Kumar, speaking on hospital spending plans, said: “There’s definitely the question—should we pause some planned purchases of new projects or expensive new equipment, or defer some things until next year.”
JPMorgan analyst Robert Marcus said that the slow pace of product launches, biopharma attracting capital at the expense of medical devices, and a broader rotation of funds into AI-related stocks have also exerted pressure on the sector.
Individual challenges such as Boston Scientific (BSX.US) and Stryker facing cyberattacks, and Baxter International (BAX.US) undergoing product recalls, have further dampened investor confidence.
Medical technology sector underperforming the wider market
RBC Capital Markets analyst Kendall Oh wrote in a report: “It will be difficult to change the narrative for the sector in 2026, but we are optimistic about the positioning for 2027.”
Marcus said a decisive win for the Democrats in the midterm elections could boost medical device stocks, even though this would not affect medical policy in the next two years. “This has not yet been reflected in valuations and could provide a decent tailwind.”
Citi’s Winsh said Zimmer Biomet (ZBH.US) is in a new product cycle, while Edwards Lifesciences (EW.US) is about to report multiple clinical trial results.
Marcus said that although Boston Scientific is “still on the ‘penalty bench’,” new product launches and data catalysts in 2027 could pave a way out of its difficulties.
Industry research’s Henriksen commented: “Long-term innovation and strong surgical volumes support generally sound fundamentals,” highlighting the sector’s resilience in the face of short-term pressure.
Evercore’s Kumar said that key advances include pulsed field ablation (a technology that treats arrhythmias using high-intensity electrical pulses), continuous glucose monitoring for diabetes, and ongoing progress in surgical robotics.
Marcus noted that overall, as medical device companies reset expectations for 2027 and win back investors, this third-quarter earnings season could be viewed as an “important clearing event.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Leerink says concerns over growth in the medical technology sector may overshadow third-quarter performance
October 9 – Leerink Partners stated that, ahead of the third-quarter earnings reports, it remains cautious on the medical technology sector and pointed out that the short-term market environment is “somewhat uncertain.” The firm noted increasing competition in some markets, including the cardiac devices and diabetes care sectors; uncertainty in surgical volumes amid rising costs; weak consumer confidence; and pressure on hospital budgets due to higher interest rates. “We believe that even if third-quarter results are positive, they may be overshadowed by ongoing market concerns about profitability and growth prospects for 2027 and beyond,” the broker said. The firm believes that positive factors for specific companies could help Medtronic (MDT.N) and Tandem Diabetes Care (TNDM.O) outperform the broader industry during these sector-wide headwinds. The broker said it remains most cautious on PROCEPT BioRobotics (PRCT.O) and Insulet (PODD.O), as a slowdown in adoption and intensifying competition may lead to lowered expectations for 2027. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or fail to capture the required context, Reuters does not guarantee the accuracy of automated translation texts, and they are provided merely for readers’ convenience. Reuters accepts no liability for any damage or loss resulting from the use of automated translation features.)
EUR/USD Price Forecast: Rallies fail above 1.1200 amid high Oil prices, debt woes
BUZZ—US Stock Market Dynamics: SpaceX, Humana, Delta Air Lines
Workspace search string for querying individual stock trends: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Brief": https://refini.tv/3dKUyB8 Reuters, October 9 — On Friday, U.S. stock index futures rose as oil prices retreated due to easing concerns over Middle East supply. However, telecom stocks remained under pressure as SpaceX's acquisition of spectrum sparked competition concerns across the telecom sector. - **T-Mobile US Inc (TMUS.O):** Hot topic — European telecom stocks fell after the SpaceX spectrum deal. [nL6N45V0EH] - **Space Exploration Technologies Corp (SPCX.O):** Hot topic — Shares rose after reaching an agreement to acquire a nationwide low-band spectrum portfolio. [nL4N45V0KP] - **Humana Inc (HUM.N):** Hot topic — Shares rose after its “Medicare Advantage” rating was raised. [nL4N45V0LU] - **Definium Therapeutics Inc (DFTX.O):** Market buzz — Shares increased after JPMorgan gave its LSD-based therapy an “Overweight” rating. [nL4N45V0NH] - **UnitedHealth Group Inc (UNH.N):** Market movement — TD Cowen lowered its target price ahead of UnitedHealth’s Q3 financial report. [nL4N45V0OU] - **Newmont Corporation (NEM.N):** - **Gold Fields Ltd (GFI.N):** - **Harmony Gold Mining Company Limited (HMY.N):** - **AngloGold Ashanti Ltd (AU.N):** Market movement — Gold miners’ shares rose in line with a slight rise in gold prices driven by a weaker dollar. [nL4N45V0PG] - **Delta Air Lines Inc (DAL.N):** Market flash — Shares fell after sharply lowering full-year profit forecast. [nL4N45V0RA] - **Apple Inc (AAPL.O):** Hot topic — Shares declined amid reports of iPhone production cuts. [nL4N45V0SB] - **Crescent Energy Company (CRGY.N):** Hot topic — Shares fell after raising 1 billion USD to acquire Devon Energy. [nL6N45V0J4] (For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. As automated translations may contain errors or may not capture the necessary context, Reuters does not guarantee the accuracy of the automated translation text, which is provided solely for readers’ convenience. Reuters accepts no liability for any damage or loss caused by the use of this function.)
BlackRock trims TAG Immobilien voting rights to 6.68% from 6.81%
BlackRock cut its total TAG voting rights to 6.68% from 6.81% on Oct. 6, 2026. Equity stake rose to 5.15% from 4.71%. Positions via instruments fell to 1.54% from 2.10%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TAG Immobilien AG published the original content used to generate this news brief via EQS News (Ref. ID: PVR_2413388_en) on October 09, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
